United States-based company that specialises in pharmaceutical aerosol product development Kenox Pharmaceuticals Inc. announced on Monday that is partnering with Lactiga US, Inc, a biotechnology company.

The collaboration is aimed at developing mucosal-targeted Secretory IgA (sIgA) therapies for immunodeficient patients. It is supported by a multi-million-dollar STTR grant awarded to Lactiga by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

This collaboration will leverage Kenox Pharmaceuticals' extensive expertise in nasal and inhaled pharmaceutical development and manufacturing. The focus of this joint effort is to accelerate the preclinical development of novel therapies designed to enhance mucosal immunity in individuals with compromised immune systems.

The grant is intended to advance Lactiga's platform sIgA technology while expanding Kenox's capabilities in inhaled and intranasal biologic delivery systems.